Tech · October 23, 2026
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Pathos AI has entered a multi-year strategic collaboration with Bristol Myers Squibb and Tempus AI to leverage artificial intelligence and genomic data in drug development. This partnership aims to enhance the discovery and development of oncology therapeutics by utilizing Pathos's AI-driven precision medicine platform alongside Tempus's vast library of clinical and molecular data. The collaboration is designed to accelerate clinical trial timelines and improve success rates for cancer treatments.
Read the original coverage
- ReutersWire
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Read at Reuters ↗ - MSNBCMainstream
Corey Lewandowski faces Justice Department inquiry, creating key test for Team Trump
Read at MSNBC ↗ - The Christian Science MonitorMainstream
Journalist Evan Gershkovich found a new beat: His imprisonment
Read at The Christian Science Monitor ↗
Reported by multiple outlets
- Pathos AI, Bristol Myers Squibb, and Tempus AI are entering a strategic collaboration.
- The partnership focuses on advancing drug development, specifically in the field of oncology.
- The collaboration involves utilizing AI technology and molecular/genomic data libraries.
Reported by only some outlets
- The partnership is described as a multi-year agreement.
- Pathos AI will utilize its proprietary PathOS platform for analysis.
Industry-friendly coverage frames it as…
emphasize the potential for AI to accelerate drug discovery timelines and improve clinical trial success rates
About these outlets
CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.